HTR1D

5-hydroxytryptamine receptor 1D · P28221 · HTR1D on Sugi Atlas →

141,086 patent compounds predicted against HTR1D, 90,800 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Naratriptan (SCHEMBL68753)	1.00	13/20
Naratriptan (SCHEMBL41527)	0.98	13/20
Naratriptan (SCHEMBL41528)	0.96	13/20
Xylometazoline (SCHEMBL34087)	1.00	12/20
Xylometazoline (SCHEMBL41837)	0.97	12/20
Oxymetazoline (SCHEMBL24301)	1.00	11/20
Zolmitriptan (SCHEMBL33336)	1.00	11/20
Zolmitriptan (SCHEMBL40595)	1.00	11/20
Oxymetazoline (SCHEMBL41247)	0.97	11/20
SCHEMBL180561	0.39	10/20
Sumatriptan (SCHEMBL41674)	0.85	9/20
SCHEMBL111992	0.58	9/20
Mebufotenin (SCHEMBL132733)	1.00	8/20
Sumatriptan (SCHEMBL1482)	1.00	7/20
5-Methoxytryptamine (SCHEMBL41982)	1.00	7/20
Sumatriptan (SCHEMBL183393)	1.00	7/20
5-Methoxytryptamine (SCHEMBL130877)	0.97	7/20
Rizatriptan (SCHEMBL41226)	0.80	7/20
SCHEMBL78477	0.66	7/20
Serotonin (SCHEMBL1495)	1.00	6/20

Clinical trials — most relevant to HTR1D by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Zomig - Treatment of Acute Migraine Headache in Adolescents	PHASE4	COMPLETED
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder	PHASE4	COMPLETED
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial	PHASE3	UNKNOWN
Vortioxetine for the Treatment of Hoarding Disorder	PHASE3	WITHDRAWN
Study of Sumatriptan Naproxen Sodium Succinate Tablets for the Treatment of Acute Migraine Attacks	PHASE3	UNKNOWN
Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury	PHASE1/PHASE2	RECRUITING
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression	PHASE1/PHASE2	RECRUITING
Serotonin-receptor Agonism in Reward Processing	PHASE2	COMPLETED
Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept	PHASE2	COMPLETED
Clinical Study of GH001 in Depression	PHASE1/PHASE2	COMPLETED
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder	PHASE2	RECRUITING
The Effect of Ginger on the Incidence of Postoperative Nausea and Vomiting	PHASE2	COMPLETED
Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a	PHASE1	COMPLETED
The Study of a Selective 5-ht6 Receptor Antagonist, HEC30654AcOH,in Healthy Subjects	PHASE1	COMPLETED
A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers	PHASE1	COMPLETED
The Neurobiological Effect of 5-HT2AR Modulation	PHASE1	RECRUITING
Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects	PHASE1	COMPLETED
Brain Imaging, Genetics and Treatment for Major Depression	PHASE1	WITHDRAWN
PET Whole Body Distribution Studies Using [11C]CUMI	nan	COMPLETED
Hormonal Causes of Menstrual-Related Mood Disorders	nan	COMPLETED
Trazodone and the Risk of Serious Adverse Events	nan	COMPLETED
The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling	nan	UNKNOWN
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED
The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers	nan	COMPLETED
Epigenetic and Neurochemical Correlates of Bipolar Disorder	nan	NOT_YET_RECRUITING
Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors	nan	COMPLETED
Investigating the Neuropsychological Effects of 5-HT2a Antagonism	nan	RECRUITING
A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.	nan	UNKNOWN
Effects of Lurasidone on Left Ventricle Systolic Functions	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a HTR1D binder may also engage these)

Protein	Name	Similarity
P56496	—	0.998	P56496 →
Q588Y6	—	0.997	Q588Y6 →
P11614	—	0.996	P11614 →
P79250	—	0.995	P79250 →
P35404	—	0.994	P35404 →
P79748	—	0.994	P79748 →
HTR1B	5-hydroxytryptamine receptor 1B	0.993	landscape →
Q9N2B6	—	0.992	Q9N2B6 →
P28564	—	0.992	P28564 →
Q60484	—	0.992	Q60484 →
P28565	—	0.991	P28565 →
P30940	—	0.991	P30940 →
Q9N2B7	—	0.990	Q9N2B7 →
O08892	—	0.990	O08892 →
Q61224	—	0.990	Q61224 →
P49144	—	0.990	P49144 →
Q9N2D9	—	0.990	Q9N2D9 →
Q6VB83	—	0.990	Q6VB83 →
O42384	—	0.990	O42384 →
Q6XXX8	—	0.990	Q6XXX8 →
O42385	—	0.989	O42385 →
P47800	—	0.989	P47800 →
P30966	—	0.989	P30966 →
P49145	—	0.989	P49145 →
Q0EAB5	—	0.988	Q0EAB5 →
P46636	—	0.988	P46636 →
A0A678XMK4	—	0.988	A0A678XMK4 →
Q9N297	—	0.988	Q9N297 →
P79400	—	0.987	P79400 →
HTR4	5-hydroxytryptamine receptor 4	0.987	landscape →